Cepivo proti demenci

diplomsko delo

Matevž Rečnik (Author), Mojca Narat (Mentor), Mojca Narat (Thesis defence commission member), Polona Jamnik (Thesis defence commission member), Nataša Štajner (Thesis defence commission member)

Abstract

Demenca v sodobnem svetu zaradi naraščajoče življenjske dobe človeka predstavlja vedno resnejši problem, s katerim se vsakodnevno spopada ogromno družin. Prav tako predstavlja tudi breme za svetovno gospodarstvo, ki letno nameni skoraj 900 milijard evrov za oskrbo obolelih. Čeprav nam mehanizmi, ki privedejo do razvoja bolezni, še vedno niso popolnoma poznani, si kljub temu prizadevamo razumeti spremembe v možganih obolelih in jih razložiti. Te pa se močno razlikujejo med različnimi oblikami demence, kar tudi otežuje razvoj zdravljenj. Pogostejše prisotne oblike demence, med katere spadajo Alzheimerjeva bolezen, Vaskularna demenca in demenca z Lewyjevimi telesci, so tako v ospredju zdravstvenih raziskav, vendar zdravljenja še vedno zajemajo zgolj lajšanje simptomov in ne odpravljajo bolezni same. Ravno zaradi tega se cepljenje v zadnjih letih tudi kaže kot vedno bolj obetavna alternativa, saj obljublja borbo proti patološkim spremembam v možganih s močjo imunskega sistema, ki je specifičen in lasten vsakemu posamezniku. Zato ne povzroča neželenih stranskih učinkov v telesu, ki so pri obstoječih zdravljenjih prisotni. Prav tako tudi obljublja zaščito pred razvojem bolezni in zdravljenje že obolelih. Do sedaj opravljene raziskave kažejo obetavne rezultate številnih cepiv, ki so v procesu kliničnih testiranj. Vse kaže na to, da bomo v prihajajočih letih uspeli premostiti probleme, ki so se pojavili pri prvih generacijah cepiv proti demenci in tako končno razvili celostno zdravljenje za večino oblik demence.

Keywords

demenca;cepiva;vakcinacija;Alzheimerjeva bolezen;vaskularna demenca;Leyeva telesca;možgani;

Data

Language:	Slovenian
Year of publishing:	2019
Typology:	2.11 - Undergraduate Thesis
Organization:	UL BF - Biotechnical Faculty
Publisher:	[M. Rečnik]
UDC:	606:616.892.3:615.371(043.2)
COBISS:	9254521
Views:	1375
Downloads:	251
Average score:	0 (0 votes)
Metadata:

Other data

Secondary language:	English
Secondary title:	Dementia vaccine
Secondary abstract:	Because of the increasing human life expectancy in the modern world, dementia represents an increasing problem to a huge part of the world's population. It also represents a burden to the world economy, since almost 900 billion euros yearly are used for the care of the afflicted. Even though the mechanisms, that lead to the development of this disease, are still not completely known to us, we aspire to understand the changes that take place in the human brain and explain them. These, however, vary greatly among the different types of dementia, which adds to the complexity of developing the cure. The most common types of this neurodegenerative disease, among which we count Alzheimer's disease, vascular dementia and dementia with Lewy bodies, represent the front of medical research, but their treatment is still based solely on relieving the symptoms, which is a far step away from curing the disease itself. Because of this, vaccination has shown itself in the last few years as an increasingly promising alternative, because it has the potential to fight the pathological changes in the brain with the strength of the immune system, which is specific and highly personalized. Because of this, it does not cause unwanted side effects in the body, that are ever so present in existing treatments. Vaccination also promises protection from developing dementia, as well as a way to treat people, who are already affected. Many tests have already shown promising effects of different drugs, which are in the process of clinical testing. Everything indicates that in the following years we are going to successfully bridge the gap between the first generation of drugs and an effective treatment for most types of dementia.
Secondary keywords:	dementia;vaccine;vaccination;Alzheimer's disease;vascular dementia;Lewy bodies;brain;
Type (COBISS):	Bachelor thesis/paper
Study programme:	0
Thesis comment:	Univ. v Ljubljani, Biotehniška fak., Študij biotehnologije
Pages:	VI, 21 str.
ID:	11187807